Welcome to our dedicated page for TELA Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on TELA Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a pioneering medical technology company based in Malvern, Pennsylvania, dedicated to transforming the field of soft tissue reconstruction. With a mission to provide advanced, cost-effective solutions, TELA Bio focuses on enhancing clinical outcomes by prioritizing the preservation and restoration of a patient's own anatomy.
The company offers two primary product lines: OviTex and OviTex PRS Reinforced Tissue Matrices. These products are designed to improve clinical outcomes and reduce costs in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. OviTex, a reinforced tissue matrix, leverages the body's natural healing response while minimizing long-term exposure to synthetic materials.
In recent developments, TELA Bio has launched LIQUIFIX, the first approved adhesive-based product for affixing mesh without penetrating patient tissue. This innovation underscores TELA Bio's commitment to providing surgeons with cutting-edge, economically viable solutions that align with modern clinical practices.
Financially, TELA Bio is experiencing significant growth. For the first quarter of 2024, the company reported a revenue increase of 39% year-over-year, reaching $16.6 million. This growth is attributed to a mature sales force, strategic product launches, and an expanding customer base. Despite operational losses, the company achieved a notable decrease in net loss, demonstrating improved financial management and operational efficiency.
Moreover, TELA Bio actively collaborates with leading surgeons to continuously innovate and address the unmet needs in soft tissue repair. The company's partnership with experts ensures that its products meet the highest standards of efficacy and safety.
For the latest updates, TELA Bio frequently hosts earnings conference calls and webcasts, providing valuable insights into its financial performance and strategic initiatives. Investors and stakeholders can access these resources via the investor section of the company's website.
In summary, TELA Bio, Inc. is a dynamic and forward-looking company poised to make significant advancements in medical technology. By combining innovation with practical solutions, TELA Bio aims to reinvigorate the soft tissue reconstruction market and provide substantial benefits to hospitals, surgeons, and patients alike.
TELA Bio, Inc. announced the hiring of D. Taylor Ocasio as the new General Counsel. With nearly ten years in corporate law and healthcare, Ocasio previously served as Deputy General Counsel at Zynerba Pharmaceuticals and held positions at Catalent Pharma Solutions and prominent law firms. CEO Antony Koblish expressed confidence in Ocasio's extensive knowledge in life sciences and corporate securities, highlighting his potential contributions to TELA's growth. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving the patient's anatomy.
TELA Bio, a medical technology company, announced its participation in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12, 2022, at 2:15 PM ET. TELA Bio focuses on soft-tissue reconstruction solutions that prioritize preserving the patient's anatomy. Management will present at the conference, and interested parties can access the live and archived webcast via their investor relations website. TELA Bio is committed to providing advanced technologies that enhance clinical outcomes while reducing reliance on permanent synthetic materials.
TELA Bio, Inc. (Nasdaq: TELA) reported strong financial results for Q4 and full year 2021, with revenues of $8.4 million for Q4, up 48%, and $29.5 million for the year, reflecting a 62% growth. Gross profit for Q4 was $5.7 million (68% margin), while full-year gross profit was $18.8 million (64% margin). Operating expenses increased to $13.3 million in Q4 and $48.3 million for the year, leading to a net loss of $8.6 million in Q4 and $33.3 million annually. TELA anticipates 2022 revenue between $40 million and $45 million, indicating continued growth despite potential COVID-19 challenges.
TELA Bio, Inc. (NASDAQ: TELA) announced its participation in the Canaccord Genuity Musculoskeletal Conference to be held on March 22, 2022, in Chicago, IL. The company aims to provide innovative soft-tissue reconstruction solutions that enhance clinical outcomes by preserving patients’ anatomy. Management will present at 3:30 PM CT, and a live and archived webcast will be accessible via their investor relations site. TELA Bio focuses on economically effective technologies that leverage natural healing responses while reducing reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced its forthcoming financial results for Q4 and full year 2021, scheduled for release on March 21, 2022. The company specializes in innovative soft-tissue reconstruction solutions that enhance clinical outcomes. A conference call will follow at 4:30 p.m. ET the same day, allowing investors to discuss the financial results. TELA prioritizes the preservation of the patient's anatomy while minimizing reliance on permanent synthetic materials. More details can be found on TELA's investor relations website.
TELA Bio, a medical technology company, has launched the SiteGuard No Rinse Antimicrobial Solution, aimed at preventing surgical site infections in plastic reconstructive surgery. Utilizing proprietary XBIO Technology, it targets bacterial biofilms that resist standard treatments, providing over five hours of protection. Early market feedback has been positive, and TELA aims to expand awareness nationwide. The product aligns with TELA's commitment to innovative soft-tissue solutions that minimize reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA) announced on February 25, 2022, the approval of stock options for 17 newly hired employees, totaling 63,800 shares. The options have an exercise price of $11.75 per share, reflecting the closing price on the grant date. These options are part of the employment agreement and will vest over four years, with 25% vesting after the first year and the rest monthly. TELA focuses on innovative soft-tissue reconstruction solutions that enhance clinical outcomes while preserving patients' anatomy.
TELA Bio reported third quarter 2021 revenue of $7.7 million, a 44% year-over-year increase. Increased demand for OviTex® products contributed to a 34% revenue rise, with OviTex PRS sales soaring 101%.
Despite challenges from COVID-19, the company maintained its full-year revenue guidance of $28.0 million to $30.0 million, reflecting growth of 54% to 65%. Operating expenses rose to $11.8 million, leading to a loss from operations of $7.2 million. Cash reserves stood at $53.6 million as of September 30, 2021.
TELA Bio announced encouraging results from the 12-month follow-up of its BRAVO study, involving 75 patients treated with OviTex Reinforced Tissue Matrix for ventral hernia repair. The data indicates a low hernia recurrence rate of 2.7%, with the final 24-month analysis showing rates below 5%. The study also reported low surgical site occurrences and significant improvements in patient quality of life. The results affirm TELA Bio's commitment to addressing the shortcomings of traditional hernia repair materials.
MALVERN, Pa., Nov. 08, 2021 - TELA Bio, Inc. (NASDAQ: TELA) announced its participation in key healthcare conferences, including the Canaccord Genuity MedTech Forum, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference. Management will present on November 18 and 22, 2021. These events focus on TELA's innovative tissue reinforcement materials aimed at improving outcomes in soft tissue reconstruction. Live webcasts will be accessible for stakeholders.
FAQ
What is the current stock price of TELA Bio (TELA)?
What is the market cap of TELA Bio (TELA)?
What does TELA Bio, Inc. specialize in?
What are the main products offered by TELA Bio?
Where is TELA Bio, Inc. located?
How has TELA Bio performed financially recently?
What recent product has TELA Bio launched?
How can investors stay updated on TELA Bio's performance?
What is OviTex?
Which market needs does TELA Bio aim to address?
Is TELA Bio publicly traded?
Who can be contacted for investor relations at TELA Bio?
